The FDA is preparing to accelerate reviews of two experimental Merck (MRK) drugs with multibillion-dollar sales potential, Patrick Wingrove and Dan Levine of Reuters reported, citing internal documents. Merck’s cholesterol treatment enlicitide decanoate and its cancer therapy sacituzumab tirumotecan have been selected for the FDA’s Commissioner’s National Priority Voucher program, a designation that could make them the seventeenth and eighteenth drugs included in the initiative, according to the documents.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck reports ‘positive’ results from Phase 3 KEYNOTE-B15 trial
- Immutep announces progress in global TACTI-004 Phase III, enrollment continues
- Adagene announces FDA fast track designation for muzastotug
- Option traders moderately bearish in Merck with shares down 0.16%
- Merck & Company: Strategic Diversification and Upcoming Catalysts Bolster Buy Rating